0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

The Clinical and Demographic Characteristics of Nonneuronopathic Gaucher Disease in 887 Children at Diagnosis FREE

Paige Kaplan, MBBCh; Hans C. Andersson, MD; Katherine A. Kacena, PhD; John D. Yee, MD, MPH
[+] Author Affiliations

Author Affiliations: Section of Metabolic Diseases, Department of Pediatrics, The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia (Dr Kaplan); Hayward Genetics Center, Tulane University Medical Center, New Orleans, La (Dr Andersson); and Genzyme Corporation, Cambridge, Mass (Drs Kacena and Yee).


Arch Pediatr Adolesc Med. 2006;160(6):603-608. doi:10.1001/archpedi.160.6.603.
Text Size: A A A
Published online

Objective  To describe the clinical and demographic characteristics of nonneuronopathic Gaucher disease (GD) in children at the time of diagnosis.

Design  Longitudinal observational database of the International Collaborative Gaucher Group Gaucher Registry.

Setting  Data reported to the Registry from January 1, 1989, to June 3, 2005, were included in this report.

Patients/Participants  All 887 patients were diagnosed as having nonneuronopathic GD from birth to younger than 18 years and did not receive enzyme replacement therapy.

Main Outcome Measures  Eight measures of the clinical manifestations and demographics of nonneuronopathic GD.

Results  The most common signs and symptoms noted were splenomegaly (95%), hepatomegaly (87%), radiologic bone disease (81%), thrombocytopenia (50%), anemia (40%), growth retardation (34%), bone pain (27%), and bone crisis (9%). Anemia and more severe splenomegaly and hepatomegaly were observed more frequently in younger patients. Skeletal manifestations were found more often in older children. Only 23% were identified as Ashkenazi Jews.

Conclusions  Nonneuronopathic GD commonly manifests in childhood and affects many ethnic groups. The high prevalence of rare mutations may be associated with earlier onset and/or more severe disease. Increased awareness of the clinical and demographic characteristics of nonneuronopathic GD in children may improve early recognition of this treatable lysosomal storage disorder, decrease morbidity, and prevent irreversible sequelae.

Figures in this Article

Gaucher disease (GD), the most common lysosomal storage disorder, is caused by a deficiency of the lysosomal enzyme glucocerebrosidase, leading to the accumulation of glucocerebroside within tissue macrophages in multiple organs.1 Gaucher disease is almost always attributable to mutations in the glucocerebrosidase gene located on the long arm of chromosome 1 and is inherited in an autosomal recessive manner. Clinically, there are 3 subtypes of GD: nonneuronopathic (type 1), acute neuronopathic (type 2), and chronic neuronopathic (type 3).

Nonneuronopathic GD is the most prevalent form (94%) and is differentiated from the acute neuronopathic (1%) and chronic neuronopathic (5%) forms by the absence of central nervous system involvement.2 The manifestations of nonneuronopathic GD include splenomegaly, hepatomegaly, anemia, thrombocytopenia, bone disease (ie, bone marrow infiltration, Erlenmeyer flask deformity of the distal femur, osteopenia, osteoporosis, infarction, avascular necrosis, and pathologic fractures), and growth retardation.24 Bone pain is common, manifesting as mild to moderate intermittent pain or more severe acute “bone crises” accompanied by periosteal elevation, leukocytosis, and fever, which may cause debilitation for several days and require narcotic analgesics. Clinical expression of GD is highly variable among patients,2 but, particularly when manifested during childhood, the natural history of GD is that of a progressive, multisystemic, and debilitating disorder.

Because GD has typically been described as an adult disorder affecting mainly Ashkenazi Jews, many physicians do not consider this diagnosis when evaluating signs and symptoms of the disorder in children. Early recognition of GD by physicians caring for children is important because safe and effective treatment with enzyme replacement is available, and early intervention can decrease morbidity and reduce the risk of later complications.5,6 Enzyme replacement therapy has been shown to prevent progressive manifestations of GD and ameliorate GD-associated anemia, thrombocytopenia, organomegaly, bone pain, and bone crises.6 Because GD is relatively uncommon in non-Ashkenazi populations (estimated incidence, 1:57 000 live births),7 no large study of the pediatric manifestations of GD has been reported. Although a previous report of the International Collaborative Gaucher Group (ICGG) Gaucher Registry data noted that most affected people manifest GD in childhood, the clinical and demographic data for childhood GD were not separately analyzed.8

This study analyzes data from the ICGG Gaucher Registry to characterize the manifestations at the time of diagnosis of a large population of children and adolescents with nonneuronopathic GD. This description of pediatric nonneuronopathic GD should increase the recognition and earlier diagnosis of this condition in childhood, allowing for the initiation of treatment before the development of severe morbidity or irreversible disease complications.

The ICGG Gaucher Registry is an observational database of clinical, biochemical, and therapeutic characteristics of patients with GD (hereafter referred to as GD patients), regardless of disease severity and treatment status.8 The ICGG Gaucher Registry, initiated in 1991 and supported by Genzyme Corporation, Cambridge, Mass, is governed by a collaborative group of international physician experts in GD (the ICGG). With appropriate institutional review board or ethics committee approvals, more than 700 physicians from 52 countries have voluntarily submitted data on their patients to the ICGG Gaucher Registry.

All nonneuronopathic GD patients included in this report were diagnosed from January 1, 1989, to June 3, 2005, ranged in age from birth to younger than 18 years at diagnosis, and had not received enzyme replacement therapy. A definitive diagnosis was based on results of enzyme analysis of glucocerebrosidase activity and/or DNA analysis of the glucocerebrosidase gene. To avoid inclusion of children who did not manifest signs or symptoms of GD, patients with a prenatal diagnosis were excluded from this study.

Patients were categorized into the following 3 groups according to age at diagnosis: birth to younger than 6 years, 6 to younger than 12 years, and 12 to younger than 18 years. For each clinical variable studied, the data closest to the diagnosis date were analyzed within an interval of ±2 years from diagnosis and before initiation of enzyme replacement therapy. Genotype frequency distributions for common, rare, and unknown mutations were determined. Hemoglobin level was analyzed as a binary variable, with anemia defined as below the reference age- and sex-adjusted value as follows: less than 10.1 g/dL for infants younger than 6 months; less than 9.5 g/dL for children 6 months to younger than 2 years; less than 10.5 g/dL for children 2 to younger than 12 years; less than 12 g/dL for boys 12 years and older; and less than 11 g/dL for girls 12 years and older. Platelet counts were analyzed in patients with intact spleens. Patients with partial or total splenectomy underwent separate analysis. Platelet counts were used to classify thrombocytopenia into the following groups: severe (<60 × 103/μL), moderate (60 × 103/μL to 120 × 103/μL), and mild/normal (>120 × 103/μL). Liver and spleen volumes were measured by means of magnetic resonance imaging, computed tomography, or ultrasonography and reported as multiples of normal size predicted for body weight (MN).9 Ultrasound measurements were converted to volumetric equivalents using the formula developed by Elstein et al.10 Splenomegaly was classified into the following groups: severe (>15 MN), moderate (>5 to 15 MN), and mild/normal (<5 MN). Hepatomegaly was divided into the following groups: severe (>2.5 MN), moderate (>1.25 to 2.5 MN), and mild/normal (≤1.25 MN).

The following 3 skeletal parameters were examined: bone pain, bone crisis, and radiologic evidence of bone disease. Bone pain was defined as being present if the patient or the parents reported this event as occurring within 1 month (30 days) before the diagnosis visit. Bone crisis was defined as present if the patient or the parents reported this event any time before diagnosis. Bone crisis was defined as pain with acute onset that requires immobilization of the affected area and narcotics for the relief of pain and that may be accompanied by periosteal elevation, elevated white blood cell count, fever, or debilitation that lasts longer than 3 days. Radiologic evidence of bone disease was tabulated.

Growth was assessed using height z scores, calculated for age and sex using the December 2000 Centers for Disease Control and Prevention growth charts11 because data on midparental heights were not available. Growth was divided into the following 3 groups: less than the 5th percentile, 5th to 25th percentile, and greater than the 25th percentile.

Data analysis was conducted using SAS software, version 8.2 (SAS Institute Inc, Cary, NC). Age group at diagnosis, sex, ethnicity, and geographic region were tabulated. Median age at diagnosis was studied across common genotype groupings. The P value test for trend in severity across age groups was calculated (Jonckheere-Terpstra 2-sided tests).12,13 We used the Jonckheere-Terpstra test to test the null hypothesis that the distribution of disease severity is the same across the 3 age groups vs the alternative hypothesis that there are significant differences among the age groups in their respective ordering for each clinical variable studied.12,13

On June 21, 2005, the ICGG Gaucher Registry contained data for 887 nonneuronopathic GD patients who had been diagnosed between birth and age younger than 18 years. Hemoglobin and platelet data from the time of diagnosis were reported for 68% and 64% of the patients, respectively; 27% of patients had data for spleen and liver volumes; and 34% had radiologic examination data. Genotype data were available for 72% of the patients.

Of the 887 total study patients, the 2 largest ethnic groups were non-Jewish white subjects (30%) and Ashkenazi Jews (23%) (Table 1). The largest groups of pediatric patients participating in the ICGG Gaucher Registry were from the United States (29%) and Latin America (25%). Europe and Israel contributed 19% and 15% of participating patients, respectively.

Table Graphic Jump LocationTable 1. Patient Demographics at Diagnosis*

Genotype data for this population indicate that 4 common mutations constitute 72% of all GD alleles: N370S, L444P, IVS2+1, and 84GG (Table 2). (The mutations are notated according to standard nomenclature.14) Two hundred twenty-five (18%) of all 1270 reported alleles were rare, and 132 (10%) were unknown. Forty-seven percent of patients had at least 1 rare or unknown allele. Patients with the N370S/N370S genotype had a median age at diagnosis of 10 years. Patients with the L444P/L444P genotype had a median age at diagnosis of 1 year. All other allele groupings had a median diagnosis age ranging from 3 to 7 years.

Table Graphic Jump LocationTable 2. Comparison of Age at Diagnosis for Different Genotype Groups

For hemoglobin levels and spleen and liver volumes, younger patients tended to have significantly more severe abnormalities at the time of diagnosis (Table 3). Across all age groups, 40% of patients had anemia; 50% had platelet counts less than 120 × 103/μL; 95% had spleen volumes greater than 5 MN; and 87% had liver volumes greater than 1.25 MN. Twenty-seven (5%) of the 570 patients submitting platelet count information reported partial or total splenectomy at the time of diagnosis, with 93% and 7% of these patients presenting with mild/normal and moderate thrombocytopenia, respectively; none had platelet counts less than 60 × 103/μL.

Table Graphic Jump LocationTable 3. Patient Hematologic and Organ Volume Characteristics at Diagnosis*

Overall, most children (81%) had at least 1 radiologic skeletal abnormality at the time of diagnosis (Table 4). The 2 most common radiologic manifestations were Erlenmeyer flask deformity (49%) and bone marrow infiltration (38%). Bone pain was reported in 27% and a history of bone crisis, in 9%. Older children had significantly (P<.001) more severe skeletal disease (Table 4). Growth was less than the 5th percentile of height for sex and age at diagnosis (Figure 1) in 34% of children (Table 4); in 28%, from the 5th to 25th percentiles; and 39%, greater than the 25th percentile.

Place holder to copy figure label and caption
Figure 1.

Height at diagnosis for 256 boys (A) and 240 girls (B) with the 5th, 50th, and 95th percentiles of the healthy population and 50th percentile reference curves for the population with Gaucher disease.

Graphic Jump Location
Table Graphic Jump LocationTable 4. Patient Skeletal Manifestations at Diagnosis*

Without definitive and uninterrupted treatment, nonneuronopathic (type 1) GD, particularly when diagnosed in childhood, is a progressive multisystemic disorder with substantial morbidity, potential for disability, reduced quality of life, and even reduced life expectancy.15 Fortunately, the underlying enzyme deficiency and resulting pathology can be treated effectively with enzyme replacement therapy (with recombinant glucocerebrosidase or imiglucerase for injection [Cerezyme]).46 However, there is reason to believe that there are children with GD that is unrecognized and undiagnosed and who may experience unnecessary morbidity and irreversible disease sequelae if treatment is not initiated at the earliest signs and symptoms. In part, this may be because nonneuronopathic GD is often thought to be an adult disorder primarily affecting or even restricted to Ashkenazi Jews.

The data described in this report clearly indicate that many patients with nonneuronopathic GD are symptomatic when they are children. Furthermore, in this international population, 77% of children who manifested nonneuronopathic GD were not Ashkenazi Jews. In fact, nonneuronopathic GD is prevalent across all ethnic groups, and many physicians caring for children can expect to encounter 1 or more children with nonneuronopathic GD in their practice.

The hematologic and organ volume factors indicate that symptoms and signs that manifest at a younger age may indicate more severe disease. Statistically significant differences in disease severity were noted among the 3 age groups. Anemia and hepatosplenomegaly at the time of diagnosis were greatest in the youngest group (birth to <6 years). Thrombocytopenia was prevalent in all age groups. This finding supports our clinical experience that the hematologic and visceral manifestations tend to appear first in the natural history of GD.

The skeletal manifestations of GD may progress slowly and only become apparent in the teenage years, although growth failure is often obvious much earlier. Exemplifying the progressive nature of skeletal pathology in GD, bone pain and bone crisis increased with the age at diagnosis. Children with GD who manifest evidence of bone pain are often incorrectly characterized as having normal growing pains. In this study, 27% of children diagnosed as having GD presented with bone pain at the time of diagnosis. Older children were more likely to have more severe radiologic manifestations of GD, with evidence of bone disease in 72% of the group diagnosed between birth and age younger than 6 years; 84%, between ages 6 and younger than 12 years; and 92%, between ages 12 and younger than 18 years.

The high prevalence of bone disease (81%) reported in children with nonneuronopathic GD at the time of diagnosis has several implications. First, evidence of early and potentially reversible bone disease is rarely evident on physical examination and may not correlate with the degree of visceral and hematologic involvement. Appropriate radiographic studies are required and must be evaluated by a radiologist familiar with the bone changes of GD. Second, the presence of severe manifestations, particularly avascular necrosis, fractures, and lytic lesions, indicates a clinically aggressive form of GD, a fact that is often unrecognized by physicians whose focus is restricted to the hematologic and visceral manifestations of GD. For many nonneuronopathic GD patients, the morbidity of bone disease has the greatest long-term impact on quality of life. Untreated bone disease can lead to severe acute and chronic pain sometimes requiring even opioid analgesia; decreased bone mass, density, and strength; and increased risk of pathologic fractures. Avascular necrosis and joint collapse may affect linear growth and require joint replacement, ambulation with crutches, and/or the use of a wheelchair. Finally, the increasing prevalence of bone disease at diagnosis among older children with GD may indicate a need for earlier diagnosis and initiation of enzyme replacement therapy to prevent or reduce the risk of irreversible bone complications.6,16

Linear growth retardation is common in the pediatric nonneuronopathic GD population, with more than 30% of all children below the fifth percentile for height at the time of diagnosis. For all 3 age groups, the median height was below the expected height based on population standards. Because most patients (66%) in our population were American, Canadian, European, or Israeli, the National Center for Health Statistics 2000 growth data11 were used for comparison. One possible explanation for the poorer growth seen in the group younger than 6 years may be more severe and earlier disease manifestations. Previous literature suggests that enzyme replacement therapy significantly improves growth in children with GD.4 The goal of treatment is to normalize growth and achieve normal peak skeletal mass within 3 years of initiating enzyme replacement therapy.17

Nonneuronopathic GD in children can be caused by a wide range of glucocerebrosidase mutations. The 4 most common mutations (N370S, L444P, 84GG, and IVS2+1) accounted for 72% of all mutated alleles in our nonneuronopathic GD population, and the remaining 28% of alleles were rare, unique, or unknown. The method of genotyping is not recorded in the ICGG Gaucher Registry, and it is possible that only common mutations were analyzed.

The manifestation of GD in childhood may indicate more severe disease than GD found in patients who present in adulthood. Childhood presentation represents an earlier accumulation of pathologic amounts of undegraded substrate in viscera and bone, which results in clinical signs and symptoms and indicates more severe disease.16 This finding agrees with our clinical experience. We believe that all children should undergo regular evaluation.

The GD in patients with the L444P/L444P genotype in this study was classified as nonneuronopathic. However, these patients are at risk for development of neuronopathic disease (type 3) in later childhood and should undergo regular evaluation for central nervous system manifestations of GD.

Although the ICGG Gaucher Registry is the largest longitudinal database of the GD population, registry data are voluntarily reported by physicians caring for GD patients and are not subject to independent verification. Therefore, the data may have limitations. First, the subjects may not represent the full spectrum of disease severity. Second, the prevalence of signs and symptoms could be biased by the identification of siblings of index cases. Third, differing testing modalities may have been used (as occurs for organ volume measurements and genotyping). Fourth, there may be variable quantities of data submitted by different physicians.

Nevertheless, the ICGG Gaucher Registry offers the largest cohort available with longitudinal data, making statistical analysis of clinical characteristics possible for a disorder in which its rarity essentially obviates the ability to conduct large-scale clinical trials.

In summary, nonneuronopathic GD is a treatable lysosomal storage disorder that most commonly manifests during childhood. A definitive diagnosis requires an enzyme assay demonstrating deficient or absent activity of glucocerebrosidase supplemented by mutational analysis of the glucocerebrosidase gene. Common disease manifestations in children include splenomegaly, hepatomegaly, anemia, thrombocytopenia, easy bruising, and significant growth retardation (Figure 2). Most patients have evidence of significant skeletal manifestations of disease, which may not be evident on physical examination and require radiologic examination for detection.16 Pediatric GD, when left untreated, is most often associated with progressive morbidity and even shortened life expectancy. All providers of health care for children should be aware of the presenting signs and symptoms of nonneuronopathic GD because the timely initiation of appropriate treatment with enzyme replacement therapy will prevent or decrease morbidity and reduce the risk of later irreversible complications of this disease.

Place holder to copy figure label and caption
Figure 2.

Prevalence of affected organ involvement in Gaucher disease among children at diagnosis. Growth retardation refers to patients below the fifth percentile for height. Radiologic evidence of bone disease may indicate Erlenmeyer flask deformity, marrow infiltration, osteopenia, avascular necrosis, infarction, and/or new fractures. Anemia is defined according to age and sex references for hemoglobin concentrations as follows: less than 11 g/dL for boys 12 years and older; less than 10 g/dL for girls 12 years and older; less than 9.5 g/dL for children aged 2 to younger than 12 years; less than 8.5 for children aged 6 months to younger than 2 years; and less than 9.1 g/dL for infants younger than 6 months. Hepatomegaly (liver volume in multiples of normal size predicted for body weight [MN]) is defined as moderate (>1.25 to 2.5 MN) to severe (>2.5 MN). Splenomegaly (spleen volume in multiples of normal) is defined as moderate (>5 to 15 MN) to severe (>15 MN). Thrombocytopenia is defined as moderate (platelet count, 60 × 103/μL to >120 × 103/μL) to severe (platelet count, <60 × 103/μL).

Graphic Jump Location

Correspondence: Paige Kaplan, MBBCh, Section of Metabolic Diseases, Department of Human Genetics and Molecular Biology, The Children's Hospital of Philadelphia, 34th and Civic Center Boulevard, Philadelphia, PA 19104 (kaplan@email.chop.edu).

Accepted for Publication: December 22, 2005.

Financial Disclosure: Dr Kaplan received an educational grant from Genzyme Corporation.

Funding/Support: This study was supported in part by Genzyme Corporation.

Acknowledgment: We thank the patients with nonneuronopathic GD and their physicians and health care personnel who submit data to the ICGG; the ICGG for their review of the manuscript; the ICGG support team; Trent Richardson, MAMS, for the graphic design of Figure 2; and Andrea Gwosdow, PhD, for assistance in preparing the manuscript.

Brady  ROKanfer  JShapiro  D Metabolism of glucocerebrosides J Biol Chem 1965;24039- 42
PubMed
Beutler  EGrabowski  GAScriver  CRedBeaudet  ALedSly  WSed  et al.  Gaucher disease The Metabolic and Molecular Bases of Inherited Disease. 8th ed New York, NY McGraw-Hill Co2001;3635- 3668
Zevin  SAbrahamov  AHadas-Halpern  I  et al.  Adult-type Gaucher disease in children Q J Med 1993;86565- 573
PubMed
Kaplan  PMazur  AManor  O  et al.  Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase J Pediatr 1996;129149- 153
PubMed Link to Article
Barton  NWBrady  RODambrosia  JM  et al.  Replacement therapy for inherited enzyme deficiency N Engl J Med 1991;3241464- 1470
PubMed Link to Article
Weinreb  NJCharrow  JAndersson  HC  et al.  Effectiveness of enzyme replacement therapy in 1028 patients with non-neuronopathic Gaucher disease after 2 to 5 years of treatment Am J Med 2002;113112- 119
PubMed Link to Article
Meikle  PJHopwood  JJClague  AECarey  WF Prevalence of lysosomal storage disorders JAMA 1999;281249- 254
PubMed Link to Article
Charrow  JAndersson  HCKaplan  P  et al.  The Gaucher Registry Arch Intern Med 2000;1602835- 2843
PubMed Link to Article
Ludwig  J Current Methods of Autopsy Practice.  Philadelphia, Pa WB Saunders Co1979;
Elstein  DHadas-Halpern  IAzuri  YAbrahamov  ABar-Ziv  YZimran  A Accuracy of ultrasonography in assessing spleen and liver size in patients with Gaucher disease J Ultrasound Med 1997;16209- 211
PubMed
Kuczmarski  RJOgden  CLGrummer-Strawn  LM  et al.  CDC growth charts: United States Adv Data 2000; ((314)) 1- 27
PubMed
Hollander  MWolfe  DA Nonparametric Statistical Methods. 2nd ed New York, NY John Wiley & Sons Inc1999;
Stokes  MEDavis  CSKoch  GG Categorical Data Analysis Using the SAS System. 2nd ed Cary, NC SAS Institute Inc2000;
Wain  HMBruford  EALovering  RCLush  MJWright  MWPovey  S Guidelines for human gene nomenclature Genomics 2002;79464- 470
PubMed Link to Article
Weinreb  NDeegan  PKacena  KMistry  PPastores  GMvom Dahl  S Life expectancy in type 1 (non-neuronopathic) Gaucher disease http://www.ashg.org/cgi-bin/ashg05s/ashg05Accessed December 9, 2005
Charrow  JAndersson  HCKaplan  P  et al.  Enzyme replacement therapy and monitoring for children with non-neuronopathic Gaucher disease: consensus recommendations J Pediatr 2004;144112- 120
PubMed Link to Article
Pastores  GMWeinreb  NJAerts  H  et al.  Therapeutic goals in the treatment of Gaucher disease Semin Hematol 2004;41(4 suppl 5)4- 14
PubMed Link to Article

Figures

Place holder to copy figure label and caption
Figure 1.

Height at diagnosis for 256 boys (A) and 240 girls (B) with the 5th, 50th, and 95th percentiles of the healthy population and 50th percentile reference curves for the population with Gaucher disease.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Prevalence of affected organ involvement in Gaucher disease among children at diagnosis. Growth retardation refers to patients below the fifth percentile for height. Radiologic evidence of bone disease may indicate Erlenmeyer flask deformity, marrow infiltration, osteopenia, avascular necrosis, infarction, and/or new fractures. Anemia is defined according to age and sex references for hemoglobin concentrations as follows: less than 11 g/dL for boys 12 years and older; less than 10 g/dL for girls 12 years and older; less than 9.5 g/dL for children aged 2 to younger than 12 years; less than 8.5 for children aged 6 months to younger than 2 years; and less than 9.1 g/dL for infants younger than 6 months. Hepatomegaly (liver volume in multiples of normal size predicted for body weight [MN]) is defined as moderate (>1.25 to 2.5 MN) to severe (>2.5 MN). Splenomegaly (spleen volume in multiples of normal) is defined as moderate (>5 to 15 MN) to severe (>15 MN). Thrombocytopenia is defined as moderate (platelet count, 60 × 103/μL to >120 × 103/μL) to severe (platelet count, <60 × 103/μL).

Graphic Jump Location

Tables

Table Graphic Jump LocationTable 1. Patient Demographics at Diagnosis*
Table Graphic Jump LocationTable 2. Comparison of Age at Diagnosis for Different Genotype Groups
Table Graphic Jump LocationTable 3. Patient Hematologic and Organ Volume Characteristics at Diagnosis*
Table Graphic Jump LocationTable 4. Patient Skeletal Manifestations at Diagnosis*

References

Brady  ROKanfer  JShapiro  D Metabolism of glucocerebrosides J Biol Chem 1965;24039- 42
PubMed
Beutler  EGrabowski  GAScriver  CRedBeaudet  ALedSly  WSed  et al.  Gaucher disease The Metabolic and Molecular Bases of Inherited Disease. 8th ed New York, NY McGraw-Hill Co2001;3635- 3668
Zevin  SAbrahamov  AHadas-Halpern  I  et al.  Adult-type Gaucher disease in children Q J Med 1993;86565- 573
PubMed
Kaplan  PMazur  AManor  O  et al.  Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase J Pediatr 1996;129149- 153
PubMed Link to Article
Barton  NWBrady  RODambrosia  JM  et al.  Replacement therapy for inherited enzyme deficiency N Engl J Med 1991;3241464- 1470
PubMed Link to Article
Weinreb  NJCharrow  JAndersson  HC  et al.  Effectiveness of enzyme replacement therapy in 1028 patients with non-neuronopathic Gaucher disease after 2 to 5 years of treatment Am J Med 2002;113112- 119
PubMed Link to Article
Meikle  PJHopwood  JJClague  AECarey  WF Prevalence of lysosomal storage disorders JAMA 1999;281249- 254
PubMed Link to Article
Charrow  JAndersson  HCKaplan  P  et al.  The Gaucher Registry Arch Intern Med 2000;1602835- 2843
PubMed Link to Article
Ludwig  J Current Methods of Autopsy Practice.  Philadelphia, Pa WB Saunders Co1979;
Elstein  DHadas-Halpern  IAzuri  YAbrahamov  ABar-Ziv  YZimran  A Accuracy of ultrasonography in assessing spleen and liver size in patients with Gaucher disease J Ultrasound Med 1997;16209- 211
PubMed
Kuczmarski  RJOgden  CLGrummer-Strawn  LM  et al.  CDC growth charts: United States Adv Data 2000; ((314)) 1- 27
PubMed
Hollander  MWolfe  DA Nonparametric Statistical Methods. 2nd ed New York, NY John Wiley & Sons Inc1999;
Stokes  MEDavis  CSKoch  GG Categorical Data Analysis Using the SAS System. 2nd ed Cary, NC SAS Institute Inc2000;
Wain  HMBruford  EALovering  RCLush  MJWright  MWPovey  S Guidelines for human gene nomenclature Genomics 2002;79464- 470
PubMed Link to Article
Weinreb  NDeegan  PKacena  KMistry  PPastores  GMvom Dahl  S Life expectancy in type 1 (non-neuronopathic) Gaucher disease http://www.ashg.org/cgi-bin/ashg05s/ashg05Accessed December 9, 2005
Charrow  JAndersson  HCKaplan  P  et al.  Enzyme replacement therapy and monitoring for children with non-neuronopathic Gaucher disease: consensus recommendations J Pediatr 2004;144112- 120
PubMed Link to Article
Pastores  GMWeinreb  NJAerts  H  et al.  Therapeutic goals in the treatment of Gaucher disease Semin Hematol 2004;41(4 suppl 5)4- 14
PubMed Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 55

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles